
Brinzopt1%
Aristopharma Ltd.
Brinzolamide ophthalmic suspension is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with: Ocular hypertension - an FDA-approved and more.
Brinzolamide ophthalmic suspension is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with:
Brinzolamide works by reducing the production of aqueous humor in the eye, thereby lowering IOP and reducing the risk of optic nerve damage and vision loss associated with glaucoma.
| Indication | Dose |
|---|---|
| Ocular hypertension / Open-angle glaucoma (adults) | Instill one drop of Brinzolamide ophthalmic suspension into the affected eye(s) three times daily. May be used alone or in combination with other IOP-lowering eye drops. |
Administration instructions:
The most common side effects of Brinzolamide (occurring in 5-10% of patients) are:
Less common side effects (1-5%) include:
Rare but serious side effects: Because Brinzolamide is a sulfonamide derivative, rare systemic hypersensitivity reactions have been reported post-marketing, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Seek immediate medical attention for skin rash, blistering, or peeling.
Brinzolamide is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.